BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events

ME Staff 8-k
-
0

BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Other Events
Item 8.01 Other Events.

On August16, 2017, BeiGene,Ltd. completed the closing of its follow-on public offering of 2,834,750 American Depositary Shares (“ADSs”), each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $71.00 per ADS, resulting in gross proceeds of approximately $201 million. This includes full exercise of the underwriters’ option to purchase additional ADSs.

Morgan Stanley, Goldman Sachs& Co. LLC, and Cowen acted as joint book-running managers. Baird and William Blair acted as co-managers.

The securities described above were offered to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (“SEC”). The final prospectus supplement relating to the offering was filed with the SEC on August11, 2017 and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to these securities may be obtained for free from the offices of Morgan Stanley& Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Goldman Sachs& Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, or email: [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, United States, Attn.: Prospectus Department or by calling 1-631-274-2806.

This Current Report on Form8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.


About BEIGENE,LTD. (NASDAQ:BGNE)

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas. It is developing its product candidate, BGB-A317, a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (PD-1), as a monotherapy and as a combination agent for various solid-organ and blood-borne cancers. It is developing BGB-290, a molecularly targeted, orally available, potent and selective inhibitor of poly ADP ribose polymerase 1 (PARP1) and PARP2, as a monotherapy and in combination with other therapies for the treatment of homologous recombination deficient cancers. It is also developing BGB-283 for the treatment of cancers.